CD8A and neoplasm: Due to the abilities of HLA-G to inhibit various immune effector cell populations including NK cells, CD8+ CTL, CD4+ T helper cells, B cells and other APC, HLA-G appears to be a potent candidate for further anti-tumor immunotherapy aiming on inhibition of immune tolerance/suppression/evasion exerted by HLA-G expressing tumors.